

FOR IMMEDIATE RELEASE

**For more information:**

Ted Glickman  
Stephens & Associates Advertising  
[ted.glickman@stephens-adv.com](mailto:ted.glickman@stephens-adv.com)  
913.213.6815

**TVAX Biomedical Secures \$2 Million Financing Round  
for Animal Health Subsidiary**

**Olathe, Kan., March 26, 2015** – TVAX Biomedical Inc., a clinical stage development company advancing novel targeted T cell based immunotherapy for the treatment of cancer, today announced it has closed a \$2 million financing round for its animal health subsidiary. The financing was led by two private investors and included Mid-America Angels, an angel investor network focused on early-stage, high-growth companies in Kansas and Missouri, and the Kansas Biosciences Authority, a venture capital fund focused on agribusiness, animal health and human health innovations.

TVAX Animal Health is focused on adapting TVAX Immunotherapy® for applications in companion animal veterinary medicine. The U.S. Department of Agriculture (USDA) has authorized the company to provide this service to veterinarians for the treatment of cancer in canine, feline and equine species.

TVAX Animal Health opened the investment offering in October 2014, with an initial goal of securing \$700,000. Shortly thereafter, the TVAX Biomedical, Inc., board of directors increased the financing threshold to \$2 million due to tremendous response from prospective investors.

“We are extremely pleased with the response to our business model from the investment community,” said Tammie Wahaus, chief executive officer, TVAX Animal Health. “There are more than three million dogs treated for cancer each year, yet the available treatment options are limited. TVAX Animal Health strives to bring effective cancer treatment options to the U.S. veterinary market, and this round of financing will help us achieve this.”

“We're thrilled to include TVAX Animal Health in Mid-America Angels' strong portfolio,” said George Hansen with Mid-America Angels. “We look forward to working with the TVAX management team to assist in the growth of this promising venture.”

more

FOR IMMEDIATE RELEASE

“The Kansas Bioscience Authority is delighted to partner with TVAX Animal Health to accelerate the company’s development of their novel T cell based therapies in an area of veterinary medicine that is well positioned for improved outcomes,” said Keith Harrington, managing director, Kansas Bioscience Authority.

Proceeds from this round of financing will be used to fund clinical trial, sales and marketing purposes.

About TVAX Biomedical, Inc.

Based in Olathe, Kan., TVAX Biomedical, Inc., is a clinical stage development company advancing its targeted T cell-based immunotherapy for the treatment of cancer. The company’s novel therapeutic approach offers the promise of improved clinical outcomes, low toxicity and the potential for fundamentally changing the way cancer is treated. TVAX Animal Health, a subsidiary of TVAX Biomedical, Inc., is focused on adapting the TVAX Immunotherapy® for applications in the veterinary sector with an initial focus on cancer in dogs. For more information, please visit [www.tvaxbiomedical.com](http://www.tvaxbiomedical.com).

###